PATENT CLAIM ANALYSIS

Application Number: 15909475
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-06
Patent Classification: ["514", "001300"]

Abstract:
The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.

Claim (Index 9):
The prodrug according to  claim 8 , wherein c is selected from fluorescein, fluorescein derivatives, simple sugars, D-amino acids or proline imino acids.

Metadata:
- Claim Count in Document: 25.0
- Percentile: 90.0
- Lexical Diversity: 1.25806
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13125732', '15297649', '15148368', '14109333', '12595482']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8296070307819857
- 35 USC 102 Novelty (BERT): 0.6192350402142367
- Combined Prediction Score: 0.8085698317252108
- Mean Citation Score: 471.85368
- Max Citation Score: 577.9419
- Similarity Product: 517.6063623195828

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test